Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ATNM | Healthcare | $1.64 | 180.62K | $49.99M | 4.55 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ATNM | Actinium Pharmaceuticals | 1.64 | 0.37 | 29.13% |
| Name | Price | % Change | |
|---|---|---|---|
| ATNM | $1.64 | +29.13% |
Actinium Pharmaceuticals (ATNM) announced that the RADIANZ clinical trial is enrolling patients. RADIANZ is an imaging study of Zr-Barecetamab-DFO using PET to guide the pan-tumor development of Ac-Barecetamab-DOTA in solid
Actinium Pharmaceuticals (ATNM) announced the formation of a Scientific Advisory Board comprising five distinguished clinicians and scientists with extensive experience in oncology, nuclear medicine and radiopharmaceutical development. The Scientific Advisory
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals and keeping the price target at $4.00. Joseph Pantginis gave his Buy rating based on several factors,
Actinium Pharmaceuticals (ATNM) announced “encouraging” initial clinical results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer, or mCRPC. The findings, presented in an oral presentation
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals and keeping the price target at $4.00. Joseph Pantginis has given his Buy rating due to a
Actinium Pharmaceuticals (ATNM) announced three presentations, including an oral presentation and two e-posters, highlighting preclinical data supporting ATNM-400’s broad potential at the 39th Annual Congress of the European Association of
The latest announcement is out from Actinium Pharmaceuticals ( ($ATNM) ). On October 15, 2026, Actinium Pharmaceuticals announced the appointment of Matt David, M.D. as Chief Financial Officer, with responsibility
Actinium Pharmaceuticals (ATNM) appointed Matt David as CFO. David joins Actinium from CorMedix, where he most recently served as EVP and Chief Business Officer. He joined CorMedix in 2020 as
Actinium Pharmaceuticals ( ($ATNM) ) has issued an announcement. On August 14, 2026, Actinium Pharmaceuticals announced significant progress in its Actimab-A program, reporting newly issued patents that broaden protection for
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals today and set a price target of $4.00. Joseph Pantginis has given his Buy rating due to a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ATNM | Nov 23, 2026TBA | $49.99M | $-0.24 | $0.00 | 0.09 | 4.55 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
